Hosted by TTP plc · 🇺🇸 US · EN · 30 episodes
Established thought leaders with verified media credentials.
What are the biggest challenges and opportunities facing the life sciences sector? How can we overcome these challenges while unlocking the opportunities? Join host Stuart Lowe and a roster of expert guests as they unpack the past, present and future of cell and gene therapy.
TTP plc hosts Invent: Life Sciences, a science show with 30 episodes published.
In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transform
In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce c
In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts a
In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a
In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva
In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industr
In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to m
The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods,
Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. With approvals for advanced therapies on the rise, and aspirations to target larger patient populations,
Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell
Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t
Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the p
Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and
Pharmaceutical companies undertake rigorous clinical trials in order to find out which drugs are safe. But in order to better protect the people volunteering for these tests, regulators decreed that data from studies on
Modern medicine has helped us develop many effective treatments for diseases found throughout the body, but we’ve yet to have the same success with the brain. The so-called 'blood brain barrier' controls the passage of m
In the pharmaceutical industry, there is a desire to go beyond the traditional ‘compound x acts on protein y,’ and achieve a more nuanced effect on the underlying biology. So, could innovative approaches to small molecul
Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthro
The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available
The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available
experts
experts
1 appearance on this show
Stuart
Helpline and Information Officer · Big Country
1 appearance on this show
Ryan Walker
alumnus of undergraduate history program · Southern New Hampshire University
1 appearance on this show
Jason Jones
Chief Analytics and Data Science Officer · Ready Fence Brisbane & Sunshine Coast
1 appearance on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Invent: Life Sciences has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Invent: Life Sciences is hosted by TTP plc. The show is categorised under science (business) and has published 30 episodes.
Invent: Life Sciences has published 30 episodes.
Invent: Life Sciences regularly covers science, business. It sits in the science category, with a business focus.
Invent: Life Sciences is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Invent: Life Sciences hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Invent: Life Sciences average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Invent: Life Sciences's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 7 days ago.
